BB BIOTECH AG
Q2 2016 Form 13-F
CIK 0000924223
· Institutional investment manager
Holdings reported by
Bellevue Group AG since Q1 2020
$2.5B Reported Value Total
Reported value
$2.5B
Quarter over quarter
-0.2%
Holdings
30
Top-10 concentration
72.7%
Filing Structure
Reports holdings for
- Biotech Target N V (not a 13F filer in our records) · File #28-11189 · Q2 2013 – Q1 2019 · declared by one filing
- Biotech Invest N V (not a 13F filer in our records) · File #28-11191 · Q2 2013 – Q1 2019 · declared by one filing
- Biotech Focus N V (not a 13F filer in our records) · File #28-11193 · Q2 2013 – Q1 2019 · declared by one filing
- Biotech Growth N V (not a 13F filer in our records) · File #28-11194 · Q4 2014 – Q1 2019 · declared by one filing
Holdings reported by
- Bellevue Group AG · since Q1 2020
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Martin Gubler / Ivo Betschart
SIGNING AUTHORITY
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2016 13F record
Q2 2016 13F filing summary
| Period of report | June 30, 2016 |
|---|---|
| Filed | August 12, 2016 |
| Form | 13F-HR |
| Reported value | $2.5B |
| Positions | 30 |
| Change in reported value | +0.7% |
| New positions | 3 |
| Exited positions | 2 |
| Position turnover | 15.6% |
| Top-10 concentration | 72.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2019 13F
Filed May 13, 2019
|
35 | $4.0B |
|
Q4 2018 13F
Filed Feb 12, 2019
|
34 | $3.1B |
|
Q3 2018 13F
Filed Nov 9, 2018
|
32 | $3.8B |
|
Q2 2018 13F
Filed Aug 9, 2018
|
32 | $3.5B |
|
Q1 2018 13F
Filed May 8, 2018
|
30 | $3.6B |
|
Q4 2017 13F
Filed Feb 14, 2018
|
30 | $3.6B |
|
Q3 2017 13F
Filed Nov 13, 2017
|
27 | $3.6B |
|
Q2 2017 13F
Filed Aug 11, 2017
|
28 | $3.3B |
|
Q1 2017 13F
Filed May 10, 2017
|
30 | $3.1B |
|
Q4 2016 13F
Filed Feb 14, 2017
|
29 | $2.7B |
|
Q3 2016 13F
Filed Nov 10, 2016
|
29 | $2.8B |
|
Q2 2016 13F
Filed Aug 12, 2016
|
30 | $2.5B |
|
Q1 2016 13F
Filed May 12, 2016
|
29 | $2.5B |
|
Q4 2015 13F
Filed Feb 9, 2016
|
30 | $3.5B |
|
Q3 2015 13F
Filed Nov 12, 2015
|
28 | $3.2B |
|
Q2 2015 13F
Filed Aug 12, 2015
|
29 | $3.7B |
|
Q1 2015 13F
Filed May 14, 2015
|
27 | $3.4B |
|
Q4 2014 13F
Filed Feb 12, 2015
|
28 | $3.1B |
|
Q3 2014 13F
Filed Nov 13, 2014
|
26 | $2.5B |
|
Q2 2014 13F
Filed Aug 7, 2014
|
24 | $2.1B |
4 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2016
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CELG Celgene Corp | $356.0M | 14.05% |
| 2 | INCY Incyte Corp. | $307.2M | 12.12% |
| 3 | GILD Gilead Sciences Inc. | $231.5M | 9.14% |
| 4 | IONS Ionis Pharmaceuticals Inc. | $165.5M | 6.53% |
| 5 | RDUS Radius Health Inc. | $160.2M | 6.33% |
| 6 | NBIX Neurocrine Biosciences Inc. | $141.9M | 5.6% |
| 7 | ALXN Alexion Pharmaceuticals Inc. | $137.7M | 5.44% |
| 8 | VRTX Vertex Pharmaceuticals Inc. | $121.8M | 4.81% |
| 9 | MDVN Medivation Inc. | $120.1M | 4.74% |
| 10 | AGIO Agios Pharmaceuticals Inc. | $99.0M | 3.91% |
| 11 | TSRO Tesaro Inc. | $97.0M | 3.83% |
| 12 | REGN Regeneron Pharmaceuticals Inc. | $71.6M | 2.83% |
| 13 | ALNY Alnylam Pharmaceuticals Inc. | $66.1M | 2.61% |
| 14 | HALO Halozyme Therapeutics Inc. | $63.7M | 2.51% |
| 15 | NVAX Novavax Inc. | $60.6M | 2.39% |
| 16 | JUNO Juno Therapeutics Inc. | $50.2M | 1.98% |
| 17 | ALDR Alder Biopharmaceuticals Inc. | $42.1M | 1.66% |
| 18 | KITE Kite Pharma Inc. | $37.5M | 1.48% |
| 19 | ICPT Intercept Pharmaceuticals Inc. | $36.5M | 1.44% |
| 20 | CEMP Cempra Inc. | $33.7M | 1.33% |
Values as reported on the Q2 2016 Form 13F. Every position is in the holdings table below.